This study evaluated the safety and tolerability of intermittent treatment over the course of 1 year with ubrogepant, a calcitonin gene-related peptide, for the acute treatment of migraine.
Headache
Original Article: Long-Term Safety of Ubrogepant for the Treatment of Migraine